https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45074 7) stratified by stroke type (ischemic stroke and intracerebral hemorrhage). Study‐specific unadjusted and adjusted RRs, controlling for confounding variables, were pooled using random‐effects meta‐analysis. National Institutes of Health Stroke Scale data were recorded in 5326 (96%) of 5570 cases with ischemic stroke and 773 (90%) of 855 participants with intracerebral hemorrhage. The pooled unadjusted female:male RR for severe ischemic stroke was 1.35 (95% CI 1.24–1.46). The sex difference in severity was attenuated after adjustment for age, pre‐stroke dependency, and atrial fibrillation but remained statistically significant (pooled RRadjusted 1.20, 95% CI 1.10–1.30). There was no sex difference in severity for intracerebral hemorrhage (RRcrude 1.08, 95% CI 0.97–1.21; RRadjusted 1.08, 95% CI 0.96–1.20). Conclusions: Although women presented with more severe ischemic stroke than men, much although not all of the difference was explained by pre‐stroke factors. Sex differences could potentially be ameliorated by strategies to improve pre‐stroke health in the elderly, the majority of whom are women. Further research on the potential biological origin of sex differences in stroke severity may also be warranted.]]> Wed 26 Oct 2022 13:58:46 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27841 Wed 23 Feb 2022 16:03:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51650 Wed 13 Sep 2023 09:53:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45752 7) and year of stroke. We estimated predictors of case-fatality and functional outcome using Poisson regression and generalized estimating equations using log-binomial models respectively at multiple timepoints. Results: Case-fatality rate was 33% at 1 month, 43% at 1 year, and 47% at 5 years. Poor functional outcome was present in 27% of survivors at 1 month and 15% at 1 year. In multivariable analysis, predictors of death at 1-month were age (per decade increase MRR 1.14 [1.07-1.22]) and SAH severity (MRR 1.87 [1.50-2.33]); at 1 year were age (MRR 1.53 [1.34-1.56]), current smoking (MRR 1.82 [1.20-2.72]) and SAH severity (MRR 3.00 [2.06-4.33]) and; at 5 years were age (MRR 1.63 [1.45-1.84]), current smoking (MRR 2.29 [1.54-3.46]) and severity of SAH (MRR 2.10 [1.44-3.05]). Predictors of poor functional outcome at 1 month were age (per decade increase RR 1.32 [1.11-1.56]) and SAH severity (RR 1.85 [1.06-3.23]), and SAH severity (RR 7.09 [3.17-15.85]) at 1 year. Conclusion: Although age is a non-modifiable risk factor for poor outcomes after SAH, however, severity of SAH and smoking are potential targets to improve the outcomes.]]> Wed 13 Mar 2024 08:50:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14369 Wed 11 Apr 2018 15:26:38 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49270 Wed 10 May 2023 12:03:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34541 Wed 09 Mar 2022 16:02:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47819 11.0 µmol/L (p = 0.012), cysteine levels were <255 µmol/L (p = 0.033) and serum folate was <22.0 nmol/L (p = 0.003; in males only). In females, dietary intake of total folate <336 µg/day (p=0.001), natural folate <270 µg/day (p = 0.011), and vitamin B2 < 1.12 mg/day (p = 0.028) was associated with an increased AD risk. These results support Hcy, Cys, and SF as useful biomarkers for AD, irrespective of APOE4 genotype and as such should be considered as part of screening and managing risk of AD.]]> Wed 01 Feb 2023 09:58:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54542 Tue 27 Feb 2024 20:40:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54206 Tue 13 Feb 2024 11:43:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36636 Thu 09 Dec 2021 11:03:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10516 Sat 24 Mar 2018 08:13:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21753 Sat 24 Mar 2018 08:03:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17291 Sat 24 Mar 2018 08:01:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20371 Sat 24 Mar 2018 07:58:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20370 Sat 24 Mar 2018 07:58:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19833 Sat 24 Mar 2018 07:57:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20967 Sat 24 Mar 2018 07:54:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19418 Sat 24 Mar 2018 07:51:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4945 Sat 24 Mar 2018 07:48:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25600 -28 for the LAS polygenic score in MO) and between MO and cardioembolic stroke (CE; p 2.7 x 10^-20 for the CE score in MO). Conclusions: Our findings indicate shared genetic susceptibility to migraine and IS, with a particularly strong overlap between MO and both LAS and CE pointing towards shared mechanisms. Our observations on MA are consistent with a limited role of common genetic variants in this subtype.]]> Sat 24 Mar 2018 07:28:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4664 Sat 24 Mar 2018 07:19:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23444 Sat 24 Mar 2018 07:13:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46624 unadjusted 1 year, -0.147; 95% CI, -0.258 to -0.036; 5 years, -0.090; 95% CI, -0.119 to -0.062). After adjustment for age, stroke severity, prestroke dependency, and depression, these pooled median differences were attenuated, more greatly at 1 year (-0.067; 95% CI, -0.111 to -0.022) than at 5 years (-0.085; 95% CI, -0.135 to -0.034). Conclusions: Women consistently exhibited poorer HRQoL after stroke than men. This was partly attributable to women's advanced age, more severe strokes, prestroke dependency, and poststroke depression, suggesting targets to reduce the differences. There was some evidence of residual differences in HRQoL between sexes but they were small and unlikely to be clinically significant.]]> Mon 28 Nov 2022 11:32:40 AEDT ]]>